Parkinsonís Disease: New, Potential Target Discovered

by Colleen Fleiss on  November 19, 2019 at 9:23 AM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

A novel mechanism for the development of Parkinson's disease, which could prove to be the starting point for the development of a more targeted therapy has been discovered by an international research team including scientists from the University of Cologne. The findings of the study are published in Nature Communications.
Parkinsonís Disease: New, Potential Target Discovered
Parkinsonís Disease: New, Potential Target Discovered

Parkinson's disease is a neurodegenerative disease in which a specific population of dopamine-producing nerve cells in the midbrain die off selectively. The resulting lack of dopamine then leads to symptoms such as resting tremors, muscle stiffness and problems executing voluntary movements.

Show Full Article


Parkinson's disease is the second most common neurodegenerative disease, affecting more than six million people worldwide. The development of Parkinson's disease is strongly age-dependent, but in many respects still not understood. Especially because many different causes - from genetic disposition and environmental factors to drug use - can contribute to its development. A causal therapy is not yet available. Therefore, there are strong efforts worldwide to better understand the molecular mechanisms of this disease.

It has been known for some that at the cellular level, disturbances in calcium-dependent signalling pathways play an important role in the development of Parkinson's disease, or are associated with it. Calcium plays a key role in many cellular signalling pathways, and its concentration is therefore regulated very precisely in the cell.

Deregulation of the calcium balance causes disturbances of the intracellular signalling cascades, which can lead to cell death. The international research team has now shown that excessive calcium influx through specific ion channels, Cav2.3 channels of the so-called R-type, can contribute significantly to the development of Parkinson's disease.

In a mouse model for Parkinson's disease, the researchers were able to prevent the death of dopamine-producing nerve cells by genetically switching off the activity of the Cav2.3 channels. The ion channel Cav2.3 has so far not been associated with Parkinson's disease. Further research on dopamine-producing neurons, which have developed from human so-called induced pluripotent stem cells, shows that signalling cascades similar to those that cause Parkinson's sensitivity in the animal models are also active in human neurons.

Previously, scientists hypothesized that another calcium channel, Cav1.3 (an L-type calcium channel), plays a central role in the development of Parkinson's disease. However, a recently completed clinical trial in which Cav1.3 channels were blocked did not show protection against Parkinson's disease. The new study provides evidence as to why this clinical trial failed to show protective effects and suggests that selective Cav2.3 inhibitors should be tested as a drug to treat Parkinson's disease.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive